Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

People who have hayfever or allergic rhinitis often complain about eye symptoms associated with their nasal symptoms. How people with hayfever develop eye symptoms is not clear. The purpose of this study is to better understand the generation of eye symptoms in patients with allergic rhinitis. We have previously shown that placing the substance that subjects are allergic to in their nose causes both nose and eye symptoms. This can be explain by a parasympathetic neurogenic reflex from the nose to the eye. Such a reflex would readily explain the tearing and watery eye symptoms, but does not explain the itch. In this study, we are going to address one possible explanation for the itch; does an axonal neurogenic reflex stimulate mast cells in the eye to release histamine, which then causes the itch? We will do this by placing an antihistamine drop in the eye and challenge the nose with allergen. We will also attempt to demonstrate that mast activation isn't effected by blocking the initiating of the reflex with a nasal steroid, as done in our previous study, and showing that the addition of an antihistamine does not add to the reduction of symptoms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen

NCT00791973

Allergic Rhinitis

COMPLETED PHASE4

Nasal Ocular Reflexes Contribute to Eye Symptoms

NCT00117832

Rhinitis, Allergic, Seasonal

COMPLETED NA

Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms

NCT00891436

Allergic Conjunctivitis to Tree Pollen or Grass Pollen

COMPLETED PHASE4

Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis

NCT01159769

Allergic Conjunctivitis

COMPLETED PHASE4

Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)

NCT00818805

Allergic Conjunctivitis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We performed a randomized, double-blind, double-dummy, placebo-controlled, four-way crossover study in 21 subjects with seasonal allergic rhinitis studied out of season. Healthy patients, between 18 and 50 years of age, came to the Nasal Physiology Laboratory at The University of Chicago for screening, where they completed an allergy questionnaire and underwent skin puncture testing for confirmation of allergy to grass or ragweed. Female subjects were given pregnancy tests. Patients who were eligible then underwent a screening nasal challenge with either grass or ragweed allergen depending on their skin test results and history. The study was approved by the Institutional Review Board at The University of Chicago and all of the patients gave written informed consent before entry.

After a 2-week washout period, after the screening challenge, 21 subjects who had positive screening challenge returned to the Nasal Physiology Laboratory where they were randomized to receive 1 week of one of four treatments:

* placebo (PL) nasal spray and PL eye drops (PL/PL),
* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),
* fluticasone furoate (FF, also known as Veramyst) nasal spray and PL eye drops (FF/PL), and
* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO).

Specifically, the PL eye drops used were lubricant eye drops with active ingredients of 0.3% glycerin and 1.0% propylene glycol and the PL nasal spray was provided by GlaxoSmithKline. Treatment with OLO consisted of 1 drop of 0.2% OLO in each eye daily and treatment of FF consisted of 2 puffs in each nostril daily, giving a total of 110 micrograms delivered in each nostril. After a week of each of the treatments, the subjects returned to the Nasal Physiology Laboratory to undergo a nasal challenge. The subjects then returned the next day while still receiving treatment for another nasal challenge to augment the nasal ocular reflex. Next, the patients had a 2-week washout period and then switched over to the next randomized treatment arm. This sequence was repeated until subjects completed all four arms of the trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Seasonal Allergic Rhinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FF/PL, PL/OLO, FF/OLO, PL/PL

Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:

* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL)
* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),
* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO), and
* placebo (PL) nasal spray and PL eye drops (PL/PL).

Group Type OTHER

PL nasal spray

Intervention Type DRUG

2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week

fluticasone furoate (FF)

Intervention Type DRUG

2 puffs of FF nasal spray in each nostril once a day for 1 week

PL eye drops

Intervention Type DRUG

1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week

olopatadine (OLO)

Intervention Type DRUG

1 drop of OLO eye drops in each eye once a day for 1 week

PL/OLO, FF/OLO, PL/PL, FF/PL

Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:

* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),
* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),
* placebo (PL) nasal spray and PL eye drops (PL/PL), and
* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL).

Group Type OTHER

PL nasal spray

Intervention Type DRUG

2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week

fluticasone furoate (FF)

Intervention Type DRUG

2 puffs of FF nasal spray in each nostril once a day for 1 week

PL eye drops

Intervention Type DRUG

1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week

olopatadine (OLO)

Intervention Type DRUG

1 drop of OLO eye drops in each eye once a day for 1 week

FF/OLO, PL/PL, FF/PL, PL/OLO

Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:

* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),
* placebo (PL) nasal spray and PL eye drops (PL/PL),
* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL), and
* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO).

Group Type OTHER

PL nasal spray

Intervention Type DRUG

2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week

fluticasone furoate (FF)

Intervention Type DRUG

2 puffs of FF nasal spray in each nostril once a day for 1 week

PL eye drops

Intervention Type DRUG

1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week

olopatadine (OLO)

Intervention Type DRUG

1 drop of OLO eye drops in each eye once a day for 1 week

PL/PL, FF/PL, PL/OLO, FF/OLO

Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:

* placebo (PL) nasal spray and PL eye drops (PL/PL),
* fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL),
* PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO), and
* FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO).

Group Type OTHER

PL nasal spray

Intervention Type DRUG

2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week

fluticasone furoate (FF)

Intervention Type DRUG

2 puffs of FF nasal spray in each nostril once a day for 1 week

PL eye drops

Intervention Type DRUG

1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week

olopatadine (OLO)

Intervention Type DRUG

1 drop of OLO eye drops in each eye once a day for 1 week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PL nasal spray

2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week

Intervention Type DRUG

fluticasone furoate (FF)

2 puffs of FF nasal spray in each nostril once a day for 1 week

Intervention Type DRUG

PL eye drops

1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week

Intervention Type DRUG

olopatadine (OLO)

1 drop of OLO eye drops in each eye once a day for 1 week

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Veramyst Olopatadine 0.2% ophthalmic solution

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females between 18 and 45 years of age.
2. History of grass and/or ragweed allergic rhinitis.
3. Positive skin test to grass and/or ragweed antigen.
4. Positive response to screening nasal challenge.

Exclusion Criteria

1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
2. Pregnant or lactating women.
3. Upper respiratory infection within 14 days of study start.
4. forced expiratory volume at one second (FEV1) \<80% of predicted at screening for subjects with history of mild asthma.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes